Sterile Intraocular Inflammation in Patients Receiving Both Faricimab and High-Dose Aflibercept in Consecutive Order.

IF 0.8 Q4 OPHTHALMOLOGY

Journal of VitreoRetinal Diseases Pub Date : 2025-08-25 DOI:10.1177/24741264251365391

Emmanuel A Dwomoh, Anisa Prasad, Tavish Nanda

{"title":"Sterile Intraocular Inflammation in Patients Receiving Both Faricimab and High-Dose Aflibercept in Consecutive Order.","authors":"Emmanuel A Dwomoh, Anisa Prasad, Tavish Nanda","doi":"10.1177/24741264251365391","DOIUrl":null,"url":null,"abstract":"Purpose: To describe 3 cases of intraocular inflammation (IOI) in patients who received faricimab and high-dose aflibercept in consecutive order. Methods: Retrospective case review. Results: Three patients, 2 with neovascular age-related macular degeneration (nAMD) and 1 with central retinal vein occlusion (CRVO), transitioned from 2 mg aflibercept to either faricimab (in cases 1 and 2) or high-dose aflibercept (in case 3) due to persistent disease activity. In all cases, contemporary medication provided minimal effect. Subsequently, patients in cases 1 and 2 were switched to high-dose aflibercept at their next visit, and the patient in case 3 was switched to faricimab. On follow-up, the disease worsened in all 3 cases. Each patient returned to their previous drug. Shortly after, each patient developed an episode of IOI. Conclusions: Patients receiving different high-dose or longer-acting agents in short order may be at risk for developing antidrug antibodies and IOI.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251365391"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378095/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251365391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To describe 3 cases of intraocular inflammation (IOI) in patients who received faricimab and high-dose aflibercept in consecutive order. Methods: Retrospective case review. Results: Three patients, 2 with neovascular age-related macular degeneration (nAMD) and 1 with central retinal vein occlusion (CRVO), transitioned from 2 mg aflibercept to either faricimab (in cases 1 and 2) or high-dose aflibercept (in case 3) due to persistent disease activity. In all cases, contemporary medication provided minimal effect. Subsequently, patients in cases 1 and 2 were switched to high-dose aflibercept at their next visit, and the patient in case 3 was switched to faricimab. On follow-up, the disease worsened in all 3 cases. Each patient returned to their previous drug. Shortly after, each patient developed an episode of IOI. Conclusions: Patients receiving different high-dose or longer-acting agents in short order may be at risk for developing antidrug antibodies and IOI.

查看原文本刊更多论文

连续服用法利西单抗和大剂量阿非利西普患者的无菌眼内炎症。

目的：描述3例连续服用法利西单抗和大剂量阿布西普的患者发生眼内炎症（IOI）的情况。方法：回顾性病例复习。结果：3例患者，2例患有新生血管性年龄相关性黄斑变性（nAMD）， 1例患有视网膜中央静脉阻塞（CRVO），由于持续的疾病活动，从2mg阿非利西普过渡到faricimab（病例1和2）或高剂量阿非利西普（病例3）。在所有病例中，当代药物的作用微乎其微。随后，病例1和2的患者在下次就诊时改用大剂量阿非利西普，病例3的患者改用法利西单抗。随访中，3例患者病情均加重。每个病人都恢复了原来的药物。不久之后，每位患者都出现了一次IOI发作。结论：短时间内接受不同大剂量或长效药物治疗的患者可能存在发生抗药抗体和IOI的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of VitreoRetinal Diseases

CiteScore

1.20

自引率

16.70%

发文量